{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:12Z","timestamp":1792011252629,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.farma.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:42:00Z","timestamp":1792010520000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Desensibilizaci\u00f3n a crisantaspasa con monitorizaci\u00f3n de la actividad enzim\u00e1tica en un paciente adulto con leucemia linfobl\u00e1stica aguda de tipo T e hipersensibilidad a L-asparaginasa"],"prefix":"10.1016","author":[{"given":"Diego","family":"Zamora-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"P\u00e9rez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreto","family":"Ruiz-Millo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"L\u00f3pez Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Panero Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"L\u00f3pez Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Climente Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.09.006_bb0005","first-page":"55","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.farma.2026.09.006_bb0010","series-title":"Serum asparaginase activity monitoring in children and adolescents","author":"O\u2019Connor","year":"2024"},{"issue":"3","key":"10.1016\/j.farma.2026.09.006_bb0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.farma.2026.09.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30891","article-title":"Desensitization using pegaspargase in the era of commercially available Erwinia: a single-institution report on efficacy, cost, and resource utilization","volume":"71","author":"Feldman","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.farma.2026.09.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31738","article-title":"Hypersensitivity to recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia and management with desensitization","volume":"72","author":"Catanzaro","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"9S","key":"10.1016\/j.farma.2026.09.006_bb0030","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.farma.2026.09.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28021","article-title":"Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"67","author":"August","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.farma.2026.09.006_bb0040","article-title":"Asparaginase activity monitoring in pediatric acute lymphoblastic leukemia: a cross-sectional nationwide study in Spain","volume":"6","author":"Lassaletta","year":"2023","journal-title":"Cancer Rep"},{"issue":"1","key":"10.1016\/j.farma.2026.09.006_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","article-title":"Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum","volume":"309","author":"Lanvers","year":"2002","journal-title":"Anal Biochem"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:42:02Z","timestamp":1792010522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326002230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S1130634326002230"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.006","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Desensibilizaci\u00f3n a crisantaspasa con monitorizaci\u00f3n de la actividad enzim\u00e1tica en un paciente adulto con leucemia linfobl\u00e1stica aguda de tipo T e hipersensibilidad a L-asparaginasa","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}